Etanercept (& biosimilar - Benepali)

BNF:

13.5.3, 10.1.3

Status:

Red

Decision Date:

None

Comments

RED^1,2,3: NICE TA373 for treating juvenile idiopathic arthritis (JIA).  (Decision date  - January 2016)

RED:^1,2,3 NICE TA375 for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. (Decision date - February 2016)

RED^1,2,3: NICE TA383 for ankylosing spondylitis and non-radiographic axial spondyloarthritis.  (Decision date - March 2016)

RED^1,2,3: NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people. (Decision date - August 2017)

RED1,2,3: NICE TA715: Adalimumab, etanercept and infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed. (Decision date - August 2021)

NHS England is the responsible commissioner for JIA and plaque psoriasis in children and young adults.

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again